Efficacy, Safety And Dosage Of Afatinib In Patients With Non-Small Cell Lung Cancer After Failure Of Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-Tki)

被引：0
|
作者：
Park, C. [1 ]
Kim, T. [1 ]
Shin, H. [2 ]
Ban, H. [2 ]
Lim, J. [1 ]
Kwon, Y. [2 ]
Oh, I. [1 ]
Kim, Y. [1 ,2 ]
Lim, S. [2 ]
Kim, Y. [1 ,2 ]
机构：
[1] Chonnam Natl Univ, Hwasun Hosp, Hawsun, Jeonnam, South Korea
[2] Chonnam Natl Univ Hosp, Gwangju, South Korea
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2016年 / 193卷
关键词：
lung cancer; EGFR; afatinib;
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A6676
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?
    Choi, Yong Won
    Choi, Jin-Hyuk
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2017, 32 (03): : 422 - 428
  • [22] Efficacy of cranial radiotherapy prior to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer patients with brain metastases
    Tsushita, N.
    Goto, Y.
    Shiraishi, H.
    Tsuruoka, K.
    Yoshida, K.
    Itahashi, K.
    Asao, T.
    Kitahara, S.
    Kanda, S.
    Horinouchi, H.
    Fujiwara, Y.
    Nokihara, H.
    Yamamoto, N.
    Ohe, Y.
    ANNALS OF ONCOLOGY, 2015, 26 : 143 - 143
  • [23] The plasma ctDNA monitoring during epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment in patients with EGFR mutant non-small cell lung cancer (JP-CLEAR trial)
    Usui, K.
    Yokoyama, T.
    Kisohara, A.
    Mori, Y.
    Takeda, Y.
    Ishida, H.
    Kusano, N.
    Kishi, K.
    Katsushima, U.
    Kuwako, T.
    Aono, H.
    Shikama, Y.
    Minato, K.
    Matsushima, H.
    Uemura, K.
    Ohashi, Y.
    Kunitoh, H.
    ANNALS OF ONCOLOGY, 2018, 29 : 514 - 514
  • [24] Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer
    Keam, Bhumsuk
    Kim, Dong-Wan
    Park, Jin Hyun
    Lee, Jeong-Ok
    Kim, Tae Min
    Lee, Se-Hoon
    Chung, Doo Hyun
    Heo, Dae Seog
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2014, 19 (04) : 594 - 600
  • [25] Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer
    Bhumsuk Keam
    Dong-Wan Kim
    Jin Hyun Park
    Jeong-Ok Lee
    Tae Min Kim
    Se-Hoon Lee
    Doo Hyun Chung
    Dae Seog Heo
    International Journal of Clinical Oncology, 2014, 19 : 594 - 600
  • [26] Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer
    Cascone, T
    Morelli, MP
    Ciardiello, F
    ANNALS OF ONCOLOGY, 2006, 17 : 46 - 48
  • [27] Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)-Pretreated Non-Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease
    Hoffknecht, Petra
    Tufman, Amanda
    Wehler, Thomas
    Pelzer, Theo
    Wiewrodt, Rainer
    Schuetz, Martin
    Serke, Monika
    Stoehlmacher-Williams, Jan
    Maerten, Angela
    Huber, Rudolf Maria
    Dickgreber, Nicolas J.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (01) : 156 - 163
  • [28] Combination effects of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) and individual chemotherapeutics in non-small cell lung cancer (NSCLC) cells with and without sensitizing-EGFR mutations
    Tsai, C.
    Chang, K.
    Chiu, C.
    Hsiao, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [29] The Efficacy and Safety of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Thymosin in Advanced Non-Small Cell Lung Cancer Patients Harboring Active Epidermal Growth Factor Receptor Mutations
    Feng, Yongdong
    Zhu, Guangkuo
    Lang, Song
    Hao, Ping
    Li, Guanghui
    Chen, Fanglin
    Zhuo, Wenlei
    Duan, Yuzhong
    Zhang, Anmei
    Chen, Zhengtang
    Sun, Jianguo
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [30] KRAS mutational status and sensitivity to a reversible epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in EGFR wild type (WT) advanced non-small cell lung cancer (NSCLC) patients (pts)
    Metro, Giulio
    Duranti, Simona
    Chiari, Rita
    Bennati, Chiara
    Molica, Carmen
    Curra, Maria Francesca
    Scafati, Chiara
    Siggillino, Annamaria
    Flacco, Antonella
    Marcomigni, Luca
    Ludovini, Vienna
    Minotti, Vincenzo
    Crino, Lucio
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345